Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta-analyses.

ABSTRACT: Individuals with Down syndrome (DS) are at high risk of developing Alzheimer's disease (AD). Discovering reliable biomarkers which could facilitate early AD diagnosis and be used to predict/monitor disease course would be extremely valuable. To examine if analytes in blood related to amyloid plaques may constitute such biomarkers, we conducted meta-analyses of studies comparing plasma amyloid beta (Aβ) levels between DS individuals and controls, and between DS individuals with and without dementia. PubMed, Embase, and Google Scholar were searched for studies investigating the relationship between Aβ plasma concentrations and dementia in DS and 10 studies collectively comprising >1,600 adults, including >1,400 individuals with DS, were included. RevMan 5.3 was used to perform meta-analyses.

SUBMITTER: Alhajraf F 

PROVIDER: S-EPMC6790908 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature